Drug developer Bionomics Ltd plans to conduct a Phase II clinical trial of its leading compound, anti-cancer drug BNC105, on 60 Mesothelioma patients in Australia next year.
|
Drug developer Bionomics Ltd plans to conduct a Phase II clinical trial of its leading compound, anti-cancer drug BNC105, on 60 Mesothelioma patients in Australia next year. |
||
|
Copyright © 2010 Mesothelioma information and other asbestos related injuries to patients, families and loved ones - All Rights Reserved |
||